In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

Approved KRAS inhibitors Lumakras and Krazati may soon face more competition as second-generation G12C inhibitors and other KRAS approaches advance.

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac in a deal that was announced in June.

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one tenth the standard dose.

Under the deal, which was first announced in September, Novartis will pay Arrowhead $200 million upfront. Arrowhead is eligible for additional payments of up to $2 billion tied to development, ...